These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33768568)

  • 21. KRAS mutation and immunohistochemical profile in intraductal papillary neoplasm of the intrahepatic bile ducts.
    Xian ZH; Qin C; Cong WM
    Pathol Res Pract; 2018 Jan; 214(1):105-111. PubMed ID: 29103773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma.
    Zhang M; Huang Y; Pan J; Sang C; Lin Y; Dong L; Shen X; Wu Y; Song G; Ji S; Liu F; Wang M; Zheng Y; Zhang S; Wang Z; Ren J; Gao D; Zhou J; Fan J; Wei W; Lin J; Gao Q
    Cancer Discov; 2023 Oct; 13(10):2248-2269. PubMed ID: 37486241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct.
    Tsai JH; Liau JY; Yuan CT; Cheng ML; Yuan RH; Jeng YM
    Histopathology; 2017 Apr; 70(5):756-765. PubMed ID: 27864998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.
    Sasaki M; Matsubara T; Nitta T; Sato Y; Nakanuma Y
    PLoS One; 2013; 8(12):e81706. PubMed ID: 24312577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice.
    Wang C; Yang W; Yan HX; Luo T; Zhang J; Tang L; Wu FQ; Zhang HL; Yu LX; Zheng LY; Li YQ; Dong W; He YQ; Liu Q; Zou SS; Lin Y; Hu L; Li Z; Wu MC; Wang HY
    Hepatology; 2012 Jan; 55(1):108-20. PubMed ID: 21932402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological characterization of so-called "cholangiocarcinoma with intraductal papillary growth" with respect to "intraductal papillary neoplasm of bile duct (IPNB)".
    Nakanuma Y; Sato Y; Ojima H; Kanai Y; Aishima S; Yamamoto M; Ariizumi S; Furukawa T; Hayashi H; Unno M; Ohta T;
    Int J Clin Exp Pathol; 2014; 7(6):3112-22. PubMed ID: 25031730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
    Sasaki M; Sato Y; Nakanuma Y
    Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of Numb promotes hepatic progenitor expansion and intrahepatic cholangiocarcinoma by enhancing Notch signaling.
    Shu Y; Xu Q; Xu Y; Tao Q; Shao M; Cao X; Chen Y; Wu Z; Chen M; Zhou Y; Zhou P; Shi Y; Bu H
    Cell Death Dis; 2021 Oct; 12(11):966. PubMed ID: 34667161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histopathological evidence of intrahepatic cholangiocarcinoma occurring in ductal plate malformation: A clinicopathologic study of 5 cases.
    Wang Q; Xu Y; Wang SM; Hu AY; Pan YC; Zhang SH
    Ann Diagn Pathol; 2021 Dec; 55():151828. PubMed ID: 34571341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumorigenesis and phenotypic characteristics of mucin-producing bile duct tumors: an immunohistochemical approach.
    Nakanuma Y; Zen Y; Harada K; Ikeda H; Sato Y; Uehara T; Sasaki M
    J Hepatobiliary Pancreat Sci; 2010 May; 17(3):211-22. PubMed ID: 19680592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma.
    Deng S; Lu X; Wang X; Liang B; Xu H; Yang D; Cui G; Yonemura A; Paine H; Zhou Y; Zhang Y; Simile MM; Urigo F; Evert M; Calvisi DF; Green BL; Chen X
    Cell Death Dis; 2024 Jun; 15(6):441. PubMed ID: 38909034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
    Zen Y
    Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice.
    Wabitsch S; Tandon M; Ruf B; Zhang Q; McCallen JD; McVey JC; Ma C; Green BL; Diggs LP; Heinrich B; Greten TF
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1166-1178. PubMed ID: 34033968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice.
    Heindryckx F; Kuchnio A; Casteleyn C; Coulon S; Olievier K; Colle I; Geerts A; Libbrecht L; Carmeliet P; Van Vlierberghe H
    J Hepatol; 2012 Jul; 57(1):61-8. PubMed ID: 22420978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
    Yang L; Niu K; Wang J; Shen W; Jiang R; Liu L; Song W; Wang X; Zhang X; Zhang R; Wei D; Fan M; Jia L; Tao K
    J Hepatol; 2024 Oct; 81(4):651-666. PubMed ID: 38679071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
    Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D
    Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.
    O'Dell MR; Huang JL; Whitney-Miller CL; Deshpande V; Rothberg P; Grose V; Rossi RM; Zhu AX; Land H; Bardeesy N; Hezel AF
    Cancer Res; 2012 Mar; 72(6):1557-67. PubMed ID: 22266220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogenic Roles of Laminin Subunit Gamma-2 in Intrahepatic Cholangiocarcinoma via Promoting EGFR Translation.
    Zhang J; Ji F; Tan Y; Zhao L; Zhao Y; Liu J; Shao L; Shi J; Ye M; He X; Jin J; Zhao B; Huang J; Roessler S; Zheng X; Ji J
    Adv Sci (Weinh); 2024 Jun; 11(21):e2309010. PubMed ID: 38526177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative clinicopathological study of biliary intraductal papillary neoplasms and papillary cholangiocarcinomas.
    Fujikura K; Fukumoto T; Ajiki T; Otani K; Kanzawa M; Akita M; Kido M; Ku Y; Itoh T; Zen Y
    Histopathology; 2016 Dec; 69(6):950-961. PubMed ID: 27410028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
    J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.